| Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
|
| Notes: |
For the most up to date list of agents funded by the Cancer Drugs Fund, please see Cancer Drug Fund list |
|
| Details... |
| 08.01 |
Cytotoxic drugs |
|
|
| 08.01 |
Side-effects of cytotoxic drugs |
|
|
| 08.01 |
Drugs for cytotoxic-induced side-effects |
|
|
Calcium Folinate
|
Formulary
|
|
|
|
Dexrazoxane (Savene®)
|
Formulary
|
|
|
|
Mesna
|
Formulary
|
|
|
|
| 08.01.01 |
Alkylating drugs |
|
|
Bendamustine
|
Formulary
|
|
 NICE TA216: Bendamustine for CLL
|
Busulfan (Tablets)
|
Formulary
|
|
|
|
Carmustine (Gliadel®)
|
Formulary
|
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
|
Chlorambucil (Tablets)
|
Formulary
|
|
|
|
Cyclophosphamide (Tablets)
|
Formulary
|
For oncology
|
|
|
Estramustine Phosphate (capsules)
|
Formulary
|
|
|
|
Lomustine (capsules)
|
Formulary
|
|
|
|
Melphalan (Tablets)
|
Formulary
|
|
|
|
Treosulfan (Capsules)
|
Formulary
|
|
|
|
| 08.01.02 |
Anthracyclines and other cytotoxic antibiotics |
|
|
Doxorubicin Hydrochloride (Lipid formulation)
|
Formulary
|
|
NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
|
Idarubicin Hydrochloride (Capsules)
|
Formulary
|
|
|
|
| 08.01.03 |
Antimetabolites |
|
|
Azacitidine (Vidaza®)
|
Formulary
|
|
NICE TA218: azacitidine for myelodysplastic syndromes
|
Capecitabine (Tablets)
|
Formulary
|
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
NICE TA191: Gastric cancer (advanced) - capecitabine
NICE TA61: Colorectal cancer - capecitabine and tegafur uracil
|
Cytarabine–daunorubicin liposomal (Vyxeos®)
|
Formulary
|
In line with NICE
|
NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
|
Fludarabine Phosphate
|
Formulary
|
|
NICE TA119: Leukaemia (lymphocytic) - fludarabine
NICE TA29: Leukaemia (lymphocytic) - fludarabine
|
Gemcitabine (Gemzar®)
|
Formulary
|
|
NICE NG85: Pancreatic cancer in adults: diagnosis and management
NICE TA116: Breast cancer - gemcitabine
|
Mercaptopurine (Tablets)
|
Formulary
|
|
|
|
Methotrexate 2.5mg (Tablets)
|
Formulary
|
|
UKMI Q&A: Should patients drink alcohol whilst taking long-term low-dose methotrexate?
UKMI Q&A: What is the clinical significance of the interaction between methotrexate and penicillins? (Oct13)
|
Pemetrexed (Alimta®)
|
Formulary
|
|
NICE TA124: Lung cancer (non-small-cell) - pemetrexed - prior chemotherapy
NICE TA135: Mesothelioma - pemetrexed disodium
NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
NICE TA402: Lung cancer (non-squamous non-small-cell) after pemetrexed and cisplatin: Pemetrexed (maintenance)
|
Raltitrexed (Tomudex®)
|
Formulary
|
|
NICE CG131:Colorectal cancer: diagnosis and management
|
Tioguanine (Tablets)
|
Formulary
|
|
|
|
Trifluridine-tipiracil (Lonsurf ®)
(Tablets)
|
Formulary
|
In line with NICE
Hospital only- NHSE commissioned
|
NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
|
| 08.01.04 |
Vinca alkaloids and etoposide |
|
|
Vinorelbine
(capsules)
|
Formulary
|
|
|
|
| 08.01.05 |
Other antineoplastic drugs |
|
|
Abemaciclib (Verzenios®)
|
Formulary
|
In line with NICE
|
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [TA579]
NICE TA 563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
|
Bosutinib (Bosulif®)
|
Formulary
|
In line with NICE
Hospital only- NHSE commissioned
|
TA401: Bosutinib for previously treated chronic myeloid leukaemia
|
Brigatinib (Alunbrig®)
|
Formulary
|
In line with NICE
|
NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
|
Carfilzomib (Kyprolis®)
|
 Restricted
|
In line with NICE
|
NICE TA457: Carfilzomib for previously treated multiple myeloma
|
Ceritinib  (Zykadia®)
|
Formulary
|
In line with NICE
|
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
|
Dabrafenib with Trametinib
|
Formulary
|
In line with NICE
|
NICE TA 544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
|
Daratumumab (Darzalex ®)
|
Formulary
|
In line with NICE
|
NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
|
Dupilumab
|
Formulary
|
In line with NICE
|
NICE TA 534: Dupilumab for treating moderate to severe atopic dermatitis
|
Durvalumab
|
Formulary
|
In line with NICE
|
Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [TA578]
|
Encorafenib with binimetinib
|
Formulary
|
In line with NICE
|
NICE TA 562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
|
Eribulin (Halaven®)
|
Formulary
|
In line with NICE
Hospital only- NHSE commissioned
|
TA423:Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
|
Ibrutinib (Imbruvica®)
|
Formulary
|
- In line with NICE
- Hospital only- NHSE commissioned
|
NICE TA 502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
NICE TA 491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
|
Idelalisib (Zydelig®)
|
Formulary
|
NHS England is responsible commissioner for its use in chronic lymphocytic leukaemia(as per NICE TA 359)
|
NICE TA 359: Idelalisib for treating chronic lymphocytic leukaemia (Oct 2015)
|
Ixazomib
|
Restricted
|
In line with NICE
Hospital only - NHSE commissioned.
|
NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
|
Lenvatinib (Kisplyx ®)
|
Formulary
|
In line with NICE
|
NICE TA 498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
NICE TA 535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
|
Midostaurin (Rydapt® )
|
Formulary
|
In line with NICE
NHSE commissioned
|
NICE TA523:Midostaurin for untreated acute myeloid leukaemia
|
Nintedanib (Vargatef ®)
|
Formulary
|
- Hospital only- NHSE commissioned
- In line with NICE and available from day 91 following publication of TA.
|
NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
|
Niraparib
|
Formulary
|
|
NICE TA 528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
|
Niraparib
|
Formulary
|
|
|
|
Olaparib (Lynparza ®![]())
|
Formulary
|
- Hospital only- NHSE commissioned
- In line with NICE and available from day 91 following publication of TA.
|
NICE TA381: Olaparib for the maintenance treatment of ovarian, fallopian tube and peritoneal cancer
|
Palbociclib (Ibrance®)
|
Formulary
|
In line with NICE
Hospital only - NHSE commissioned
|
NICE TA 495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
|
|
Panobinostat (Farydak®
|
Formulary
|
Hospital only- NHSE commissioned
In line with NICE and available from day 91 following publication of TA.
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
|
Pegaspargase (Oncaspar®)
|
Restricted
|
Hospital only- NHSE Commissioned
In line with NICE and available from day 91 following publication of TA.
|
NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia-
|
Pembrolizumab (Keytruda®)
|
Formulary
|
NHS England is responsible commissioner in line with NICE (see links below)
|
NICE TA 557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
NICE TA 366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab (Nov 2015)
NICE TA 540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
NICE TA 357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (Oct 2015)
|
Ribociclib (Kisqali®)
|
Formulary
|
In line with NICE
Hospital only - NHSE commissioned
|
NICE TA 496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
|
|
Ruloxitinib (Jakavi®
|
Formulary
|
Hospital only- NHS England is responsible commissioner
In line with NICE and available from day 91 following publication of TA (see links below)
|
NICE TA 386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
|
Talimogene laherparepvec (Imlygic®)
|
Formulary
|
Hospital only- NHS E commissioned
In line with NICE and available from day 91 following publication of TA (see link below)
|
NICE TA410: Unresectable metastatic melanoma- Talimogene laherparepvec
|
Tisagenlecleucel (Kymriah®)
|
Formulary
|
In line with NICE
|
NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
|
Osimertinib
|
Formulary
|
In line with NICE
|
TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
|
Venetoclax (Venclyxto® )
|
Formulary
|
In line with NICE
|
NICE TA 487: Venetoclax for treating chronic lymphocytic leukaemia
NICE TA 561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
|
| 08.01.05 |
Amsacrine |
|
|
| 08.01.05 |
Arsenic trioxide |
|
|
Arsenic Trioxide (Trisenox®)
|
Formulary
|
|
NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
|
| 08.01.05 |
Bevacizumab |
|
|
Bevacizumab
|
Formulary
|
Funding available through Cancer Drugs Fund (CDF) for indications listed in CDF list.
Click here to access latest CDF list.
|
NICE TA212: Colorectal cancer (metastatic) - bevacizumab
NICE TA214: Breast Cancer with taxane
NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
NICE TA263: Breast cancer with capecitabine
NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
|
| 08.01.05 |
Bexarotene |
|
|
Bexarotene
(capsules)
|
Formulary
|
|
|
|
| 08.01.05 |
Bortezomib |
|
|
Bortezomib (Velcade®)
|
Formulary
|
In line with NICE
|
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
NICE TA311: Multiple myeloma - bortezomib (induction therapy
NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
NICE TA129: Multiple myeloma - bortezomib
|
| 08.01.05 |
Brentuximab vedotin |
|
|
Brentuximab vedotin (Adcetris®)
|
Formulary
|
|
NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
|
| 08.01.05 |
Cetuximab |
|
|
Cetuximab (Erbitux®)
|
Formulary
|
|
NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
NICE TA145: Head and neck cancer - cetuximab
NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
NICE TA439:Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
|
| 08.01.05 |
Crisantaspase |
|
|
Crisantaspase (Erwinase®)
|
Formulary
|
|
|
|
| 08.01.05 |
Dacarbazine and Temozolomide |
|
|
Dacarbazine
|
Formulary
|
|
|
|
Temozolomide (Temodal®)
(capsules)
|
Formulary
|
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
NICE TA23: Brain cancer - temozolomide
|
| 08.01.05 |
Erlotinib |
|
|
Erlotinib (Tarceva® )
|
Formulary
|
in line with NICE and available from day 91 following publication of TA.
|
NICE TA374: Lung cancer (non-small cell, locally advanced or metastatic)- erlotinib and gefitinib after prior chemotherapy
NICE TA258: Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)
NICE TA227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)
|
| 08.01.05 |
Hydroxycarbamide |
|
|
Hydroxycarbamide
|
Formulary
|
For myeloproliferative disorders.
Supported by an ESCA (in development)
For use in sickle cell- see chapter 9
|
|
|
| 08.01.05 |
Ipilimumab |
|
|
Ipilimumab (Yervoy®)
|
Formulary
|
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
|
| 08.01.05 |
Mitotane |
|
|
Mitotane (Lysodren®)
(tablets)
|
Formulary
|
|
|
|
| 08.01.05 |
Panitumumab |
|
|
Panitumumab (Vectibix®)
|
Formulary
|
|
NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
|
| 08.01.05 |
Pentostatin |
|
|
| 08.01.05 |
Platinum compounds |
|
|
Oxaliplatin
|
Formulary
|
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
|
| 08.01.05 |
Porfimer sodium and temoporfin |
|
|
| 08.01.05 |
Procarbazine |
|
|
Procarbazine
(capsules)
|
Formulary
|
|
|
|
| 08.01.05 |
Protein kinase inhibitors |
|
|
Afatinib (Giotrif®)
|
Formulary
|
In line with NICE
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
|
Alectinib
|
Formulary
|
In line with NICE
|
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
|
Cabozantinib (Cabometyx®)
|
Formulary
|
In line with NICE
|
NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
|
Crizotinib (Xalkori®)
|
Restricted
|
Hospital only- NHSE commissioned
In line with NICE
|
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE TA406:Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE TA 529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
|
Dasatinib (Sprycel®)
|
Formulary
|
In line with NICE
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
|
Everolimus (Afinitor®)
|
Formulary
|
In line with NICE
Hospital only-NHSE commissioned
|
NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
|
Everolimus (Votubia®)
|
Formulary
|
|
|
|
Gefitinib (Iressa®)
|
Formulary
|
|
NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
|
Imatinib (Glivec®)
|
Formulary
|
in line with NICE
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA326: Gastrointestinal stromal tumours - imatinib (adjuvant): guidance
NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib. NOT RECOMMENDED
NICE TA86: Gastro-intestinal stromal tumours (GIST) - imatinib
|
Lapatinib (Tyverb®)
|
Formulary
|
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
|
Nilotinib (Tasigna®)
|
Formulary
|
In line with NICE
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
|
Pazopanib (Votrient®)
|
Formulary
|
|
NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib
|
Ponatinib (Iclusig®)
|
Formulary
|
In line with NICE
|
NICE TA451:Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
|
Regorafenib (Stivarga® )
|
Formulary
|
In line with NICE
NHS E commissioned
|
NICE TA 555:Regorafenib for previously treated advanced hepatocellular carcinoma
NICE TA 488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
|
Sorafenib (Nexavar®)
|
Formulary
|
|
NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
|
Sunitinib (Sutent®)
|
Formulary
|
|
NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
NICE TA179: Gastrointestinal stromal tumours - sunitinib
NICE TA178: Renal cell carcinoma
NICE TA169: Renal cell carcinoma - sunitinib
|
Temsirolimus (Torisel®)
|
Formulary
|
|
NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma
NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
|
Tivozanib (Fotivda®)
|
Formulary
|
In line with NICE
|
NICE TA512:Tivozanib for treating advanced renal cell carcinoma
|
Vemurafenib (Zelboraf®)
|
Formulary
|
In line with NICE
|
NICE TA176: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
|
| 08.01.05 |
Taxanes |
|
|
Cabazitaxel (Jevtana®)
|
Restricted
|
In line with NICE
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (updated Aug 2016)
|
Docetaxel
|
Restricted
|
In line with NICE
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and management
NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
|
Paclitaxel
|
Restricted
|
In line with NICE
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and management
NICE TA55: Ovarian cancer - paclitaxel (review)
|
Paclitaxel - Albumin Bound Formulation (Abraxane®)
|
Restricted
|
In line with NICE
|
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
|
| 08.01.05 |
Topoisomerase I inhibitors |
|
|
Topotecan (Hycamtin®)
|
Restricted
|
In line with NICE
|
NICE TA183: Cervical cancer (recurrent) - topotecan
NICE TA184: Lung cancer (small-cell) - topotecan
NICE TA389: Ovarian cancer (recurrent) - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine
|
| 08.01.05 |
Trabectedin |
|
|
| 08.01.05 |
Trastuzumab |
|
|
Pertuzumab (Perjeta®)
|
Formulary
|
In line with NICE
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
|
Trastuzumab (Herceptin®)
|
Formulary
|
In line with NICE
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and management
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
NICE TA34: Breast cancer (advanced)- trastuzumab
|
Trastuzumab emtansine (Kadcyla®)
|
Formulary
|
In line with NICE
|
NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
|
| 08.01.05 |
Tretinoin |
|
|
| 08.01.05 |
Vismodegib |
|
|
| 08.02 |
Drugs affecting the immune response |
|
|
| 08.02 |
Immunosuppressant therapy |
|
|
| 08.02.01 |
Antiproliferative immunosuppressants |
|
|
Azathioprine
(tablets/suspension)
|
Formulary
|
Oncology/haematology
|
ESCA: Azathioprine in conjunction with prednisolone in ILD.
ESCA Azathioprine (dermatology)
ESCA: Azathioprine in IBD
ESCA: Azathioprine in RA or PA.
UKMI Q&A: Can mothers breastfeed while taking azathioprine?
|
Mycophenolate Mofetil
(tablets/suspension/capsules)
|
Formulary
|
Renal Post transplant- new patients
Renal Post transplant-patients initiated pre April 2013
- For use in connective tissue diseases (Rheumatology)Click here
|
|
|
Mycophenolate Sodium (Myfortic®)
|
Formulary
|
|
|
|
|
|
| 08.02.02 |
Corticosteroids and other immunosuppressants |
|
|
AdoPORT® (Tacrolimus)
|
Formulary
|
|
|
|
Ciclosporin (Neoral® Sandimmun®)
(capsules/solution)
|
Formulary
|
Post transplant- new patients
Post transplant-patients initiated pre April 2013
|
|
|
Sirolimus (Rapamune®)
(tablets/solution)
|
Formulary
|
Post transplant- new patients
Post transplant-patients initiated pre April 2013
|
|
|
Tacrolimus
(immediate- release)
|
Formulary
|
Prescribe by brand name only to minimise the risk of inadvertent switching between products, which has been associated with reports of toxicity and graft rejection (June 2012)
- Prograf ®: immediate- release capsule, twice daily dosage
Post transplant- new patients
Post transplant-patients initiated pre April 2013
|
|
|
Tacrolimus
(prolonged-release)
|
Formulary
|
Prescribe by brand name only and do not switch to minimise the risk of inadvertent switching between products, which has been associated with reports of toxicity and graft rejection (June 2012)
- Advagraf ®: prolonged release capsule, once daily dosage
Post transplant- new patients
Post transplant-patients initiated pre April 2013
|
|
|
|
|
|
|
| 08.02.03 |
Anti-lymphocyte monoclonal antibodies |
|
|
Alemtuzumab (Lemtrada®)
|
Formulary
|
In line with NICE
|
NICE TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis
|
Atezolizumab (Tecentriq®)
|
Formulary
|
In line with NICE
|
NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
NICE TA 492: Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
|
Avelumab (Bavencio®)
|
Formulary
|
- Hospital only
- In line with NICE
|
NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
|
Blinatumomab (Blincyto®)
|
Formulary
|
In line with NICE
|
NICE TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
|
Dinutuximab
|
Formulary
|
In line with NICE
|
NICE TA 538: Dinutuximab beta for treating neuroblastoma
|
Gemtuzumab (Mylotarg®)
|
Formulary
|
In line with NICE
|
NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
|
Inotuzumab ozogamicin (Besponsa ®)
|
Formulary
|
In line with NICE
Hospital only- NHSE commissioned
|
NICE TA 541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
|
Nivolumab (Opdivo®)
|
Formulary
|
In line with NICE
Hospital only- NHSE Commissioned
|
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma [TA581]
NICE TA 558:Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
NICE TA 490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
NICE TA 484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
NICE TA 483: Nivolumab for previously treated squamous non-small-cell lung cancer
NICE TA 462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
NICE TA 417: Nivolumab for previously treated advanced renal cell carcinoma
NICE TA 400: Nivolumab in combination with ipilimumab for treating advanced melanoma
|
Obinutuzumab (Gazyvaro®)
|
Formulary
|
In line with NICE
Hospital only- NHS England commissioned
|
NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma
NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
NICE TA343: Untreated chronic lymphocytic leukaemia- obinutuzumab in combination with chlorambucil
|
Ocrelizumab
|
Formulary
|
In line with NICE
|
NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis
|
Ofatumumab (Arzerra®)
|
Formulary
|
NHS England is responsible commissioner for its use in untreated chronic lymphocytic leukaemia (as per NICE TA 344)
|
NICE TA202: Chronic lymphocytic leukaemia refractory to fludaribine and alemtuzumab - ofatumumab is NOT recommended
NICE TA344: Untreated Chronic lymphocytic leukaemia- ofatumumab in combination with chlorambucil or bendamustine.
NICE TA470: Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal)
|
Rituximab
|
Formulary
|
NHSE is the responsible commissioner.In line with NICE
|
NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma
NICE TA226: Lymphoma (follicular non-Hodgkin’s) - rituximab
NICE TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab
NICE TA174: Leukaemia (chronic lymphocytic, first line) - rituximab
NICE TA 561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
NICE TA137: Lymphoma (follicular non-Hodgkin’s) - rituximab
|
| 08.02.04 |
Other immunomodulating drugs |
|
|
Axicabtagene ciloleucel (YESCARTA®)
|
Formulary
|
|
NICE TA 559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
|
Cladribine (Mavenclad®)
(tablets)
|
Formulary
|
In line with NICE
Hospital only- NHSE commissioned
|
NICE TA 493: Cladribine tablets for treating relapsing–remitting multiple sclerosis
|
Pomalidomide (Imnovid®)
|
Formulary
|
|
NICE TA 427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
|
Sarilumab (Kevzara®)
|
Formulary
|
In line with NICE
Commissioned by CCGs.
|
NICE TA 485: Sarilumab for moderate to severe rheumatoid arthritis
|
|
|
| 08.02.04 |
Interferon Alfa |
|
|
Interferon Alfa
|
Restricted
|
Hospital only
In line with NICE
|
NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
|
Peginterferon Alfa
|
Restricted
|
Hospital only
In line with NICE
|
NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
NICE TA200: Hepatitis C - peginterferon alfa & ribavirin
NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
|
| 08.02.04 |
Interferon beta |
|
|
Interferon Beta (Avonex®)
|
Formulary
|
|
|
|
Interferon Beta (Betaferon®)
|
Formulary
|
|
|
|
Interferon beta (Extavia®)
|
Formulary
|
|
|
|
Interferon Beta (Proleukin®)
|
Formulary
|
|
|
|
Interferon Beta (Rebif®)
|
Formulary
|
|
|
|
| 08.02.04 |
Interferon gamma |
|
|
| 08.02.04 |
Aldesleukin |
|
|
| 08.02.04 |
BCG bladder instillation |
|
|
| 08.02.04 |
Canakinumab |
|
|
| 08.02.04 |
Dimethyl fumarate |
|
|
Dimethyl fumarate (Tecfidera®)
|
Formulary
|
For use in relapsing-remitting Multiple Sclerosis- NHSE commissioned
In line with NICE
|
NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
|
| 08.02.04 |
Fingolimod |
|
|
Fingolimod
|
Restricted
|
In line with NICE
|
NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
|
| 08.02.04 |
Glatiramer acetate |
|
|
Glatiramer Acetate (Copaxone®)
|
Formulary
|
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
|
| 08.02.04 |
Histamine |
|
|
| 08.02.04 |
Lenalidomide, pomalidomide, and thalidomide |
|
|
Lenalidomide
|
Restricted
|
In line with NICE
|
NICE TA171: Multiple myeloma - lenalidomide
NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma
|
Thalidomide capsules
|
Formulary
|
In line with NICE
|
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
|
| 08.02.04 |
Mifamurtide |
|
|
Mifamurtide
|
Restricted
|
In line with NICE
|
NICE TA235: Mifamurtide for the treatment of osteosarcoma
|
| 08.02.04 |
Natalizumab |
|
|
Natalizumab (Tysabri®)
|
Restricted
|
In line with NICE
|
NICE TA127: Multiple sclerosis - natalizumab
|
| 08.02.04 |
Teriflunomide |
|
|
Teriflunomide (Aubagio®)
|
Restricted
|
In line with NICE
|
NICE TA303: Teriflunomide for relapsing remitting MS
|
| 08.03 |
Sex hormones and hormone antagonists in malignant disease |
|
|
| 08.03.01 |
Oestrogens |
|
|
Diethylstilbestrol
(tablets)
|
Formulary
|
|
|
|
| 08.03.02 |
Progestogens |
|
|
Medroxyprogesterone Acetate
|
Formulary
|
|
|
|
Megestrol Acetate
|
Formulary
|
|
|
|
Norethisterone
|
Formulary
|
|
|
|
| 08.03.03 |
Androgens |
|
|
| 08.03.04 |
Hormone antagonists |
|
|
| 08.03.04.01 |
Breast cancer |
|
|
Anastrozole
|
Formulary
|
|
|
|
Exemestane
|
Formulary
|
|
|
|
Fulvestrant (Faslodex®)
|
Formulary
|
|
NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
|
Letrozole
|
Formulary
|
|
|
|
Tamoxifen
|
Formulary
|
|
|
|
|
|
|
|
|
|
|
|
| 08.03.04.02 |
Prostate cancer and gonadorelin analogues |
|
|
|
|
|
|
| 08.03.04.02 |
Gonadorelin analogues |
|
|
Degarelix
|
Formulary
|
- Commissioned by CCGs, in line with NICE
- Transfer to Primary Care supported by an ESCA. Click here
to access
|
NICE TA404:Degarelix for treating advanced hormone-dependent prostate cancer
|
| 08.03.04.02 |
Anti-androgens |
|
|
Abiraterone (Zytiga®)
|
Formulary
|
|
NICE TA259: Abiraterone for castration resistant prostate cancer
NICE TA387: Abiraterone for metastatic hormone-relapsed prostate cancer before chemotherapy
|
Bicalutamide
(tablets)
|
Formulary
|
|
|
|
Buserelin
(nasal spray)
|
Formulary
|
Listed in Chapter 6 for other indications
|
|
|
Cyproterone Acetate
(tablets)
|
Formulary
|
|
|
|
Enzalutamide (Xtandi®)
|
Restricted
|
Hospital only- NHSE commissioned
In line with NICE and available from day 91 following publication of TA.
|
NICE TA377: Metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
|
Flutamide
|
Formulary
|
|
|
|
Goserelin (Zoladex®)
|
Formulary
|
|
|
|
Goserelin (Zoladex® LA)
|
Formulary
|
|
|
|
Leuprorelin Acetate (Prostap® 3)
|
Formulary
|
|
|
|
Leuprorelin Acetate (Prostap® SR)
|
Formulary
|
|
|
|
Triptorelin- Decapeptyl® SR
|
Formulary
|
Accepted on formulary January 2017 following new drug application.
cost-effective alternative to current formulary options and a longer administration interval.
|
|
|
| 08.03.04.02 |
Gonadotrophin-releasing hormone antagonists |
|
|
| 08.03.04.03 |
Somatostatin analogues |
|
|
Lanreotide (Somatuline Autogel®)
|
Formulary
|
Palliative Care use only
Oncology
Acromegaly
|
|
|
Lanreotide (Somatuline® LA)
|
Formulary
|
Palliative Care use only
Oncology
Acromegaly
|
|
|
Lutetium (177Lu) oxodotreotide
|
Formulary
|
In line with NICE
Hospital only - NHSE commissioned
|
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
|
Octreotide (Sandostatin Lar®)
|
Formulary
|
Palliative Care use only
Oncology
Acromegaly
|
|
|
Octreotide (Sandostatin®)
|
Formulary
|
Palliative Care use only
Oncology
Acromegaly
|
|
|
| .... |
| Non Formulary Items |
Aflibercept (Zaltrap®)
|
Non Formulary
|
Negative NICE TA |
 NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
|
Aldesleukin (Proleukin®)
|
Non Formulary
|
|
|
|
Amifostine (Ethyol®)
|
Non Formulary
|
|
|
|
Amsacrine (Amsidine®)
|
Non Formulary
|
|
|
|
Axitinib (Inlyta®)
|
Non Formulary
|
|
|
|
Calcium Leofolinate (Isovorin®)
|
Non Formulary
|
|
|
|
Canakinumab (Ilaris®)
|
Non Formulary
|
Terminated appraisal: TA302 - Canakinumab for treating systemic juvenile idiopathic arthritis |
|
|
Carboplatin (Paraplatin®)
|
Non Formulary
|
|
|
|
Daclizumab
|
Non Formulary
|
NICE TA withdrawn March 2018. See MHRA update |
NICE TA441: Daclizumab for treating relapsing–remitting multiple sclerosis
|
Daclizumab (Zenapax®)
|
Non Formulary
|
|
|
|
Disodium Folinate (Sodiofolin®)
|
Non Formulary
|
|
|
|
Disodium Levofolinate
|
Non Formulary
|
|
|
|
Envarsu XR
|
Non Formulary
|
|
|
|
Envarsus
|
Non Formulary
|
|
|
|
Ethinylestradiol
|
Non Formulary
|
|
|
|
Fampridine
|
Non Formulary
|
|
|
|
Goserelin-Zoladex®
|
Non Formulary
|
|
|
|
Histrelin (Vantas®)
|
Non Formulary
|
|
|
|
Irinotecan Hydrochloride (Campto®)
|
Non Formulary
|
Negative NICE TA |
Negative NICE TA 307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Negative NICE TA 440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
|
Oxaliplatin (Eloxatin®)
|
Non Formulary
|
|
|
|
Padeliporfin (TOOKAD®)
|
Non Formulary
|
|
NICE TA546: Padeliporfin for untreated localised prostate cancer
|
Palifermin (Kepivance®)
|
Non Formulary
|
|
|
|
Pentostatin (Nipent®)
|
Non Formulary
|
|
|
|
Porfimer Sodium
|
Non Formulary
|
|
|
|
Temoporfin (Foscan®)
|
Non Formulary
|
|
|
|
Toremifene (Fareston®)
|
Non Formulary
|
|
|
|
Trabectedin (Yondelis®)
|
Non Formulary
|
|
NICE TA185: Soft tissue sarcoma - trabectedin
NICE TA222- ovarian cancer
|
Tretinoin
|
Non Formulary
|
|
|
|
Triptorelin (Gonapeptyl Depot®)
|
Non Formulary
|
|
|
|
Vandetanib (Caprelsa®)
|
Non Formulary
|
|
NICE TA550: Vandetanib for treating medullary thyroid cancer
|
Vindesine Sulphate (Eldisine®)
|
Non Formulary
|
|
|
|
Vinflunine (Javlor®)
|
Non Formulary
|
|
NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine
|
Vismodegib (Erivedge®)
|
Non Formulary
|
Negative NICE TA |
Negative NICE TA 489: Vismodegib for treating basal cell carcinoma
|
| |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Prescribing in children
The APC notes that the informed use of unlicensed medicines or of licensed medicines for unlicensed applications (‘off-label’ use) is often necessary in paediatric practice.
The APC advises GPs to consider specialist prescribing recommendations for Green and Amber medicines that are not subject to ESCAs or RICaDs in combination with the information provided in the BNFC which goes beyond that of marketing authorisations. The BNFC has been designed for rapid reference and the information presented has been carefully selected to aid decisions on prescribing.
|
|
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications. |
|
Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate, or initiation and maintenance of prescribing in Primary Care following recommendation from a Specialist.
Some amber medicines require agreement with the local (internal) medicines committee prior to initiation; others may require a framework to support safe transfer and maintenance of care such as a RICaD or ESCA. The Formulary will be annotated to reflect these requirements. |
|
Medicines for initiation and maintenance prescribing by Specialists only |
|
Non-formulary medicines- medicines not recommended for routine primary care prescribing. |
|
Positive NICE TA and /or awaiting local clarification on place in therapy ; Please contact your Medicines Optimisation team for more information. |
|
|
|
